MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan

About this update from Medicinova, Inc.

[{"type":"text","content":"LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover the combination of MN-166 (ibudilast) and riluzole for alleviating the negative effects of ALS, treating a patient diagnosed with ALS, and slowing progression of disease in a patient diagnosed with ALS. The allowed claims cover a wide range of doses and dosing regimens for both MN-166 (ibudilast) and riluzole. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, \"We are very pleased to receive notice that this new patent will be granted. We believe it could substantially increase the potential value of MN-166 as patients are using the combination of MN-166 and riluzole in our ongoing Phase 3 clinical trial in ALS. Previously, a similar patent was granted in the U.S., the U.S. FDA granted both orphan-drug designation and fast-track designation to MN-166 for the treatment of ALS, and the European Commission granted Orphan Medicinal Product Designation to MN-166 for the treatment of ALS.\" About ALS Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The nerves lose the ability to trigger specific muscles, which causes the muscles to become weak. As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed. Life expectancy of an ALS patient is usually 2-5 years. According to the ALS Association, there are approximately 20,000 ALS patients in the U.S. and approximately 5,000 people in the U.S. are diagnosed with ALS each year. About MN-166 (ibudilast) MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 an...

More updates from Medicinova, Inc.